- Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments.
- Beijing's BeiGene was approved to manufacture the company's approved anti-PD-1 antibody at its new Guangzhou facility.
- Invesco has launched a new China Healthcare Equity fund to offer a diversified portfolio of China-listed healthcare companies.
For further details see:
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between 2 San Diego-China Oncology Biopharmas